DRKTY yields 28.37% · JNJ yields 2.13%● Live data
📍 DRKTY pulled ahead of the other in Year 1
Combined, DRKTY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DRKTY + JNJ for your $10,000?
Darktrace plc, together with its subsidiaries, engages in the development and sale of cyber-threat defense technology solutions in the United Kingdom, the United States, Europe, and internationally. Its products include Darktrace PREVENT, an attack surface management that continuously monitors attack surface for risks, high-impact vulnerabilities and external threats; and Darktrace DETECT, which analyzes thousands of metrics to reveal subtle deviations that may signal an evolving threat, including unknown techniques and novel malware, as well as installs in minutes, identifies threats, and avoids disruption. The company's products also include Darktrace RESPOND that works autonomously to disarm attacks whenever they occur and reacts to threats in seconds, as well as works 24/7 as it frees up security teams and resources; and Darktrace HEAL, which enables organizations to restore assets and systems affected by cyber-attacks to trusted operational states through AI assistance, as well as security teams to make quick and confident decisions to keep the business up and running. It serves various areas of public sectors, global enterprises and small-to-midsize businesses, critical infrastructure, and industrial organizations, including technology, governments, global retailers, financial and insurance, healthcare, and telecommunications. The company was founded in 2013 and is headquartered in Cambridge, the United Kingdom.
Full DRKTY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.